EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

t(14;22)(q32;q11) translocation involving IGH and IGL acquired at progression of splenic marginal zone lymphoma treated with rituximab, ibrutinib, and obinutuzumab

Julia T Geyer, Jia Ruan, Michael J Kluk, Liming Bao

Annals of Hematology · 2025

DOI: 10.1007/s00277-025-06282-5 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Annals of Hematology, 2025. Verfasst von Julia T Geyer und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Chromosomes, Human, Pair 14, Chromosomes, Human, Pair 22, Immunoglobulin Heavy Chains. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Translocations involving immunoglobin (IG) are common in B-cell neoplasms. These IG translocations lead to the disposition of the enhancer or promoter of an IG locus, typically IGH, to a proto-oncogene, resulting in the elevated expression of the cancer gene. IG fusions play an important role in the diagnosis, prognostication, and therapy selection of B-cell lymphomas. A t(14;22)(q32;q11) translocation involving IGH and IGL is rare in lymphomas. We report herein clinicopathological characteristics, response to treatment, and outcomes of a first splenic marginal zone lymphoma case with a t(14;22)(q32;q11) translocation involving IGH and IGL treated with rituximab, ibrutinib, and obinutuzumab. Studies of additional cases are needed to elucidate the potential role of the t(14;22) translocation in lymphomagenesis and prognostication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsChromosomes, Human, Pair 14Chromosomes, Human, Pair 22Immunoglobulin Heavy ChainsLymphoma, B-Cell, Marginal ZoneSplenic NeoplasmsTranslocation, GeneticHumansAdenineAntibodies, Monoclonal, HumanizedDisease ProgressionPiperidinesProto-Oncogene MasPyrazolesPyrimidinesRituximab

Stichwörter der Autor:innen

IGH and IGLSplenic marginal zone lymphomaTranslocationt(14;22)(q32;q11)

Substanzen

AdenineAntibodies, Monoclonal, HumanizedibrutinibImmunoglobulin Heavy ChainsMAS1 protein, humanobinutuzumabPiperidinesProto-Oncogene MasPyrazolesPyrimidines

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
  • Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
  • Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA. bal4006@med.cornell.edu.
  • Department of Pathology and Laboratory Medicine, Weill Cornell Medical College of Cornell University, 1300 York Avenue, New York, NY, 10065, USA. bal4006@med.cornell.edu.

Zitieren

APA

Geyer, J. T., Ruan, J., Kluk, M. J., & Bao, L. (2025). t(14;22)(q32;q11) translocation involving IGH and IGL acquired at progression of splenic marginal zone lymphoma treated with rituximab, ibrutinib, and obinutuzumab. Annals of Hematology. https://doi.org/10.1007/s00277-025-06282-5

Vancouver

Geyer JT, Ruan J, Kluk MJ, Bao L. t(14;22)(q32;q11) translocation involving IGH and IGL acquired at progression of splenic marginal zone lymphoma treated with rituximab, ibrutinib, and obinutuzumab. Annals of Hematology. 2025. doi:10.1007/s00277-025-06282-5

BibTeX
@article{Geyer2025,
  author = {Geyer, Julia T and Ruan, Jia and Kluk, Michael J and Bao, Liming},
  title = {t(14;22)(q32;q11) translocation involving IGH and IGL acquired at progression of splenic marginal zone lymphoma treated with rituximab, ibrutinib, and obinutuzumab},
  journal = {Annals of Hematology},
  year = {2025},
  doi = {10.1007/s00277-025-06282-5}
}
Kostenlos starten →